Genocea Biosciences Inc EBITDA margin
¿Qué es el EBITDA margin de Genocea Biosciences Inc?
El EBITDA margin de Genocea Biosciences Inc es -2,788.23%
¿Cuál es la definición de EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin de compañías en Sector Health Care en NASDAQ en comparadas con Genocea Biosciences Inc
¿Qué hace Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Empresas con ebitda margin similar a Genocea Biosciences Inc
- Inovio Pharmaceuticals tiene EBITDA margin de -2,850.67%
- WayPoint Biomedical tiene EBITDA margin de -2,849.14%
- UroGen Pharma Ltd tiene EBITDA margin de -2,821.65%
- Syros Pharmaceuticals tiene EBITDA margin de -2,796.41%
- Saint Jean Carbon tiene EBITDA margin de -2,796.21%
- Volt Carbon Technologies Inc tiene EBITDA margin de -2,796.21%
- Genocea Biosciences Inc tiene EBITDA margin de -2,788.23%
- AssetOwl tiene EBITDA margin de -2,784.76%
- Sprott Physical Silver Trust tiene EBITDA margin de -2,779.39%
- Nex Metals Explorations tiene EBITDA margin de -2,766.11%
- Ascendis Pharma A/S tiene EBITDA margin de -2,759.32%
- GobiMin tiene EBITDA margin de -2,734.72%
- Transition Metals tiene EBITDA margin de -2,718.30%